An announcement from CareDx ( (CDNA) ) is now available.
CareDx announced its financial results for the fourth quarter and full year of 2024, reporting a 19% increase in total revenue to $333.8 million. The company saw significant growth in testing services revenue and volume, with a notable improvement in net income and adjusted EBITDA compared to the previous year. The company also highlighted its strategic focus on expanding testing services and payer coverage, positioning itself for continued growth in 2025. The Board of Directors authorized a common stock repurchase program of up to $50 million, indicating confidence in the company’s financial health and future prospects.
More about CareDx
CareDx, Inc., based in Brisbane, California, is a leading precision medicine solutions company specializing in the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. The company offers testing services, products, and digital healthcare solutions throughout the pre- and post-transplant patient journey, and is a prominent provider of genomics-based information for transplant patients.
YTD Price Performance: -2.93%
Average Trading Volume: 811,093
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.12B
For an in-depth examination of CDNA stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com